BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 12, 2007
View Archived Issues
Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD
Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today)
Read More
Missed Endpoint Won't Doom Future of Gattex, NPS Vows
Read More
CombinatoRx Stock Offering Nets $33M For Thick Pipeline
Read More
Hemispherx Files Ampligen NDA: First Therapy For CFS?
Read More
Pharmaxis Raises $45M To Push Late-Stage Pulmonary Drugs
Read More
CuraGen Shuts Down Program Following 2nd Phase II Failure
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More